Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553778 | 0.81 | PAK4 (0.40) | PAK4PKN1TNK2JAK3PAK1 | |
| SCHEMBL15041860 | 0.75 | TNK2 (0.39) | TNK2SRC | |
| SCHEMBL13553877 | 0.74 | PKN1 (0.52) | PAK4PKN1TNK2PAK1ABL1 | |
| SCHEMBL15787963 | 0.74 | TNK2 (0.43) | PAK4PKN1TNK2JAK3PAK1 | |
| SCHEMBL15036038 | 0.74 | PAK4 (0.47) | PAK4PKN1TNK2JAK3PAK1 | |
| SCHEMBL15036118 | 0.74 | SRC (0.45) | PAK4PKN1TNK2PAK1ABL1 | |
| SCHEMBL15041532 | 0.74 | TNK2 (0.43) | PAK4PKN1TNK2PAK1 | |
| SCHEMBL14682011 | 0.72 | PAK4 (0.47) | PAK4PKN1TNK2JAK3PAK1 | |
| SCHEMBL15785286 | 0.72 | PAK4 (0.48) | PAK4PKN1TNK2JAK3PAK1 | |
| SCHEMBL15787829 | 0.72 | PKN1 (0.56) | PAK4PKN1TNK2JAK3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | PAK4 5/4885PKN1 534/4885TNK2 14/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK4 5/4885PKN1 326/4885TNK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.